Colonoscopy After a Positive Blood Test: How GI Practices Bill It

Last Updated: November 6, 2026
Table of Contents
Colonoscopy After Positive Blood Test: KX Billing 2026

How do you bill a colonoscopy after a positive blood test?

As of November 2026, a colonoscopy that follows a positive Medicare-covered blood-based colorectal cancer test is a screening service that GI practices bill as G0121 or G0105 with modifier KX. The patient owes no deductible or coinsurance when no tissue is removed, and the usual screening frequency limit does not apply. If the gastroenterologist removes a polyp, the claim moves to the therapeutic CPT code with modifier PT.

Coverage basis: CMS added blood-based tests to its “complete” colorectal cancer screening policy starting January 1, 2025.

Two tests now in play: Guardant Health’s Shield and Freenome’s SimpleScreen CRC, which Abbott launched on September 30, 2026.

Tissue removal changes the claim: Polypectomy and biopsy codes take modifier PT, with coinsurance falling from 15% to 10% on January 1, 2027.

What Changed With SimpleScreen’s Launch

Blood-based colorectal cancer screening stopped being a one-product category this fall. On July 24, 2026, the FDA approved Freenome’s SimpleScreen CRC as the second blood test cleared for average-risk adults 45 and older, according to the American Gastroenterological Association. Abbott, which holds exclusive U.S. rights, launched the test on September 30, 2026, and eligible Medicare Part B patients pay nothing out of pocket for it.

On October 27, 2026, Becker’s ASC Review published an analysis of what blood-based screening means for GI centers that put numbers on the shift. Guardant Health reported roughly 66,000 Shield tests in the second quarter of 2026, up from about 16,000 a year earlier, and raised its 2026 forecast to 270,000 to 285,000 tests. UnitedHealth Group also became the first major commercial insurer to cover Shield.

For a GI practice, the blood test itself is not the billing event. The ordering provider and the laboratory handle that claim. The claim that lands on your billing team’s desk is the colonoscopy that follows a positive result, and that claim has its own rules.

Since January 1, 2025, Medicare has treated a follow-on colonoscopy after a positive Medicare-covered blood-based biomarker test as part of a complete colorectal cancer screening, according to CMS MLN Matters MM14031. The colonoscopy is billed and paid as screening, not diagnostic, and CMS clarified that screening frequency limits do not apply to it.

The result is a growing referral stream most GI billing teams have not built a workflow around. Coding it correctly protects the patient’s zero-cost benefit and keeps claims from coming back unprocessed.

Does a colonoscopy after a positive blood test count as screening?

Yes, under Original Medicare. When a Medicare-covered blood-based biomarker test returns a positive result, the follow-up colonoscopy is a screening colonoscopy under the complete colorectal cancer screening policy. The patient pays no deductible or coinsurance for the screening service, and standard screening frequency limits do not apply to that follow-on procedure.

The word “covered” matters. According to First Coast Service Options, the Medicare Administrative Contractor for Florida, Medicare covers blood-based biomarker screening once every three years for patients aged 45 to 85 who are asymptomatic and at average risk. The test must be FDA market-authorized for colorectal cancer screening, processed by a CLIA-certified laboratory, and meet published sensitivity and specificity thresholds. A blood test that falls outside those criteria does not trigger the complete screening benefit, so the follow-up colonoscopy may not qualify as screening.

Medicare Advantage is where the rules start to diverge. Abbott has said Medicare Advantage patients may face cost-sharing for SimpleScreen, and each MA plan sets its own policy for the follow-up procedure. Some MA plans publish coding guidance that mirrors Original Medicare, using G0121 or G0105 with modifier KX. Others apply plan-specific edits or prior authorization rules.

Commercial coverage is the least settled. UnitedHealth Group covers Shield, but cost-sharing for a colonoscopy after a positive blood test varies by plan and employer group. As of November 2026, the safest practice is to verify benefits for every follow-up colonoscopy before the procedure date, document the positive result in the chart, and record the payer’s answer in the patient account.

Why Blood Tests Are Reshaping GI Referrals

The most common issue we see providers run into is not the coding itself. It is the gap between a positive blood test and a completed colonoscopy, because every follow-up that never reaches the schedule is a screening patient lost and a claim never billed.

The data on that gap is sobering. Becker’s October 27 analysis cited a UCLA study of 6,068 patients who received Shield from 2022 to 2024. About 7.4% had abnormal results. Only 49% of those with at least six months of follow-up had a colonoscopy within six months, and 56% had one at any point. Medicare Advantage patients were 74% less likely than privately insured patients to follow up within six months after adjustment.

There is also an upside for GI practices. About one in three U.S. adults in the screening age range has never been screened, according to Stanford Medicine research cited in the same analysis. If blood tests reach those patients and positive results are routed to colonoscopy, they add procedure volume rather than replace it.

Clinical guidance still favors colonoscopy. The American Cancer Society added a blood test option on May 27, 2026, but kept colonoscopy as its primary recommendation. In the pivotal trial analysis, SimpleScreen detected 81.1% of colorectal cancers but 13.7% of advanced precancerous lesions.

For the revenue cycle, this turns referral tracking into a billing task. Intake staff need to know a referral came from a positive non-invasive test, schedulers need to book it as screening, and coders need the flag in front of them on the date of service. Patient cost conversations also change on January 1, 2027, which we cover in our breakdown of colonoscopy billing changes for 2027.

What does a follow-up colonoscopy claim look like?

A clean Medicare claim for a follow-up colonoscopy with no findings reports G0121, or G0105 for a high-risk patient, with modifier KX. When the physician removes a polyp or takes a biopsy, the practice reports the therapeutic CPT code, such as 45385 or 45380, with modifier PT, and Medicare applies the reduced coinsurance.

Coinsurance figures below follow the phase-down set by the Consolidated Appropriations Act, 2021.

Encounter scenarioCodeModifierPatient cost, 2026 dates of servicePatient cost, 2027 dates of service
Follow-up colonoscopy, no tissue removedG0121 or G0105KXNo deductible, no coinsuranceNo deductible, no coinsurance
Follow-up colonoscopy, polyp removed by snare45385PTDeductible waived, 15% coinsuranceDeductible waived, 10% coinsurance
Follow-up colonoscopy with biopsy45380PTDeductible waived, 15% coinsuranceDeductible waived, 10% coinsurance
Anesthesia, procedure stays screening00812NoneNo deductible, no coinsuranceNo deductible, no coinsurance
Anesthesia, procedure becomes therapeutic00811PTDeductible waived, reduced coinsuranceDeductible waived, reduced coinsurance
Moderate sedation, procedure stays screeningG0500 or 9915333No deductible, no coinsuranceNo deductible, no coinsurance

Two rules trip up even experienced coders. First, modifier KX belongs only on G0121 or G0105. It does not go on polypectomy or biopsy codes, and Medicare guidance says KX and PT should not be used together on the same line. When tissue is removed, the therapeutic code carries modifier PT alone. Our CPT 45385 guide walks through snare polypectomy coding in detail.

Second, Medicare returns a follow-up claim missing KX as unprocessable, typically with CARC 16 and RARC N822 or N823. Adding the modifier and resubmitting fixes it, but every return delays payment.

One nuance: MAC billing pages, including First Coast’s, still describe KX in terms of stool-based tests, while CMS extended complete screening to blood-based tests in 2025. As of November 2026, confirm your MAC’s current instructions before finalizing your claim edit.

How should GI practices prepare for more blood-test referrals?

GI practices should flag every referral that follows a positive blood-based test, confirm the test was Medicare-covered, verify benefits by payer type, and build claim edits that require modifier KX on G0121 or G0105 for these encounters. Billing teams should also track positive-result referrals until the colonoscopy is completed and billed.

  • Add a referral intake field for a positive non-invasive screening result, including the test name and result date.
  • Confirm the blood test was FDA-approved and Medicare-covered, since only covered tests trigger the complete screening benefit.
  • Verify Medicare Advantage and commercial benefits before scheduling, because cost-sharing rules vary by plan.
  • Build a claim scrubber edit that requires modifier KX on G0121 or G0105 whenever the intake flag is present.
  • Train coders to switch to the therapeutic CPT code with modifier PT, never KX, when tissue is removed.
  • Update patient cost estimates for dates of service on or after January 1, 2027, when the coinsurance drops to 10%.
  • Run a monthly open-referral report so positive results that never reach the schedule get a follow-up call.

One question we hear constantly from practice managers is whether their current billing team can absorb a new screening workflow on top of everything else changing in 2027. For many independent GI groups, the honest answer is that the workflow exists on paper but nobody owns the edits, the tracking, or the denial follow-up.

Providers often come to us after a batch of follow-up colonoscopy claims comes back unprocessed for a missing modifier. If your team needs a GI billing partner that already runs KX, PT, and screening workflows, we can connect you with one in as little as 30 minutes.

Common Mistakes on Follow-Up Claims

Across the billing companies in our network, a recurring pattern is that follow-up colonoscopy errors cluster around a few predictable decisions made at the coding desk.

Coding the follow-up as diagnostic. Some coders see an abnormal test result and default to 45378. That strips the screening benefit, bills the patient a deductible and coinsurance they should not owe, and invites a complaint and a refund.

Putting KX on the wrong line. Appending KX to a polypectomy or biopsy code, or pairing KX with PT on the same line, creates processing errors that delay payment.

Holding claims on frequency grounds. Internal scrubbers built around the 10-year screening interval can flag these claims as too soon. Frequency limits do not apply to a follow-on screening colonoscopy, so the edit needs an exception.

Assuming every payer follows Original Medicare. Medicare Advantage and commercial plans set their own rules. A claim coded perfectly for Original Medicare can still deny under an MA plan with different requirements.

Mishandling the supporting codes. Screening diagnosis sequencing, anesthesia code selection, and sedation modifiers all affect cost-sharing. Our guides on Z12.11 colon cancer screening and modifier 33 cover the details that keep the whole claim aligned.

In-House vs. Outsourced Screening Billing

Handling follow-up colonoscopies in-house works when a practice has a dedicated GI coder, a scrubber it can configure, and someone assigned to work returned claims within days. Many independent practices have one or two of those pieces, not all three. When the coder who understands KX leaves, the knowledge leaves with them.

Outsourcing makes sense when the screening workflow touches more people than your team can coordinate. A specialized GI billing company already maintains edits for screening and therapeutic conversions, tracks MAC instruction changes, and works payer-specific rules for Medicare Advantage plans. That is the difference between learning the KX rule from a returned claim and never seeing the return in the first place.

In our experience matching providers with billing partners, GI practices get the best results when they choose a company based on specialty depth rather than price alone. Tim Daniels, Director of Strategic Accounts at Billing Service Quotes, personally reviews each request submitted through Gastroenterology Billing and factors in procedure volume, payer mix, EHR platform, and whether the practice bills an ambulatory endoscopy center.

The Billing Service Quotes network has matched more than 2,000 providers across all 50 states. Many billing companies in the network are software agnostic and work inside gGastro, Provation, Epic, athenahealth, and other platforms GI practices already use. Rates start as low as 2.95%, and matching is free for providers.

Frequently Asked Questions

Is SimpleScreen CRC covered by Medicare?

Yes. According to Abbott, Medicare covers SimpleScreen CRC, and eligible Part B patients pay nothing out of pocket for the test. Coverage follows Medicare’s blood-based biomarker criteria, which apply to asymptomatic, average-risk patients aged 45 to 85, once every three years. Medicare Advantage patients may face cost-sharing depending on their plan.

What modifier is used for a colonoscopy after a positive blood test?

Medicare uses modifier KX on G0121 or G0105 to identify a follow-up screening colonoscopy within a complete colorectal cancer screening. KX tells the claims system the requirements of the medical policy were met. If tissue is removed, the practice reports the therapeutic CPT code with modifier PT instead of KX.

Can modifier KX and modifier PT be used together?

Not on the same line. Modifier KX belongs on the screening G-code when the follow-up colonoscopy has no tissue removal. Modifier PT belongs on the therapeutic CPT code, such as 45385 or 45380, when a polyp is removed or a biopsy is taken. Mixing them on one line causes processing errors.

Does the 10-year screening interval apply to a follow-up colonoscopy?

No. CMS clarified that screening frequency limitations do not apply to a follow-on screening colonoscopy performed as part of a complete colorectal cancer screening. Practices should make sure internal scrubber edits built around the standard 10-year interval include an exception for these encounters so claims are not held or written off.

Do Medicare Advantage plans waive cost-sharing for the follow-up colonoscopy?

It depends on the plan. Some Medicare Advantage plans publish guidance that mirrors Original Medicare, using G0121 or G0105 with modifier KX and no member cost-sharing. Others apply their own rules or authorization requirements. Verify benefits with each MA plan before scheduling and document the response in the patient account.

What happens if modifier KX is left off the claim?

Medicare returns the screening colonoscopy claim as unprocessable, typically with claim adjustment reason code 16 and remark code N822 or N823. The practice must add modifier KX and resubmit. The claim is not denied outright, but each returned claim delays payment and adds rework for the billing team.

Next Steps

Get matched with a GI billing company that bills follow-up colonoscopies right the first time. Free for providers, with rates starting as low as 2.95%.

Get Matched In 30 Minutes

Get a FREE Quote

Tell us about your practice and we'll connect you with trusted billing companies.

100% Free to providers — No hidden fees at any stage

Tim Daniels
Online now
Tim Daniels

How can I help?

Send me your number and I'll personally call you in less than 24 hours to discuss any questions you may have about our gastroenterology billing partners

Mon–Fri, 9:00am–5:30pm Or email instead →
Got it — talk soon.
I'll call you within one business hour. Check your phone for an unknown number.